Vitalia co-founders Niklas Anzinger and Laurence Ion today announced that they will be leading two new, separate organizations, Viva City and Infinita City.
“Together, we built Vitalia from the ground up, establishing a foundation that has led us to this exciting new chapter,” said Anzinger and Ion in a joint statement. “This decision stems from our shared recognition that our unique perspectives can best flourish in two distinct organizations, each with its own approach. Both companies remain committed to accelerating biomedical innovation, and we look forward to building on our shared legacy in complementary directions.”
Laurence Ion will lead Viva City, which will concentrate on building a city within a special regulatory zone governed by its residents, to accelerate medical innovation and extend healthy lifespan.
Niklas Anzinger will head Infinita City, which will concentrate on special regulatory zones as a path to acceleration.
“We extend our gratitude to our community, partners, and investors, whose trust has been pivotal,” added Anzinger and Ion. “We are eager to share our next steps and invite you to join us on these parallel journeys. Vitalia will forever continue in our shared memory.”
Joint Statement of Vitalia Co-founders
We are excited to announce that we are moving forward along two paths to best pursue our respective visions.
Together, we built Vitalia from the ground up, establishing a foundation that has led us to this exciting new chapter.
Laurence will lead Viva City, which will concentrate on building a city within a special regulatory zone governed by its residents, to accelerate medical innovation and extend healthy lifespan. It can be followed on these new channels: Website | Linktree
Niklas will head Infinita City, which will concentrate on special regulatory zones as a path to acceleration, which can be followed on these new channels: Website | Linktree
This decision stems from our shared recognition that our unique perspectives can best flourish in two distinct organizations, each with its own approach.
Both companies remain committed to accelerating biomedical innovation, and we look forward to building on our shared legacy in complementary directions.
We extend our gratitude to our community, partners, and investors, whose trust has been pivotal. We are eager to share our next steps and invite you to join us on these parallel journeys.
Vitalia will forever continue in our shared memory.
Niklas Anzinger & Laurence Ion
Vitalia
